All In MedTech

Device Trial Radar · NCT03584295

Early Extubation by ECCO2R Compared to IMV in Patients with Severe Acute Exacerbation of COPD

A Multicentre, Randomized-controlled Trial of EXtracorporeal CO2 Removal to Facilitate Early Extubation Compared to Invasive Mechanical Ventilation in Patients with Severe Acute Exacerbation of COPD (X-COPD)

Last checked: Nov 20, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

18

Actual

Start

Feb 7, 2023

Primary completion

Nov 1, 2024

Study completion Nov 25, 2024

Sponsor

Lead sponsor
Xenios AGNot on our public-company list
Sponsor type
Industry
Collaborators
Winicker Norimed GmbH
First posted
Jul 12, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to investigate if veno-venous (vv)-extracorporeal carbon dioxide Removal (ECCO2R) is capable of reducing mortality and/or severe disability at day 60 after randomisation in patients with severe acute exacerbation of chronic obstructive pulmonary disease (COPD) requiring invasive mechanical ventilation (IMV). Extubation will be facilitated by VV-ECCO2R and compared to IMV alone in a randomized controlled trial.

Conditions

  • COPD Exacerbation

Interventions

  • Extracorporeal carbon dioxide removalDevice

    Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R to facilitate early extubation

  • Conventional CareOther

    Patient with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional Care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Death or severe disabilityTime frame: day 60

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kliniken der Stadt Köln gGmbH, ARDS and ECMO Zentrum Köln-Merheim

    Cologne, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.